BRARTEMICIN-ANALOGUE
DE602018091344T2Active Publication Date: 2026-05-13VICTORIA LINK LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- VICTORIA LINK LTD
- Filing Date
- 2018-11-02
- Publication Date
- 2026-05-13
AI Technical Summary
Technical Problem
Current adjuvants that stimulate the Mincle receptor for enhancing cellular immunity are either highly toxic or difficult to synthesize, limiting their use as therapeutic agents.
Method used
Development of brartemicin analogues with long lipophilic tails that act as potent Mincle agonists, stimulating a Th1 immune response and serving as effective vaccine adjuvants.
Benefits of technology
The brartemicin analogues induce robust inflammatory cytokine production and enhance antigen-specific immune responses, demonstrating potent adjuvant activity both in vitro and in vivo.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.